Atai Life Sciences (ATAI) Competitors $1.42 +0.03 (+2.16%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATAI vs. OCUL, IOVA, SNDX, COLL, ELVN, WVE, DYN, GPCR, CMRX, and CDMOShould you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Wave Life Sciences (WVE), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Atai Life Sciences vs. Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Collegium Pharmaceutical Enliven Therapeutics Wave Life Sciences Dyne Therapeutics Structure Therapeutics Chimerix Avid Bioservices Ocular Therapeutix (NASDAQ:OCUL) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends. Is OCUL or ATAI more profitable? Atai Life Sciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Ocular Therapeutix's return on equity of -45.18% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Atai Life Sciences N/A -65.75%-52.71% Which has preferable valuation & earnings, OCUL or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M18.79-$80.74M-$1.26-5.98Atai Life Sciences$308K894.95-$40.22M-$0.93-1.49 Do institutionals & insiders have more ownership in OCUL or ATAI? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, OCUL or ATAI? Ocular Therapeutix has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Do analysts recommend OCUL or ATAI? Ocular Therapeutix currently has a consensus target price of $16.38, indicating a potential upside of 117.46%. Atai Life Sciences has a consensus target price of $10.50, indicating a potential upside of 655.40%. Given Atai Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Atai Life Sciences is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OCUL or ATAI? In the previous week, Ocular Therapeutix had 10 more articles in the media than Atai Life Sciences. MarketBeat recorded 11 mentions for Ocular Therapeutix and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Ocular Therapeutix's score of 0.66 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Ocular Therapeutix Positive Atai Life Sciences Very Positive Does the MarketBeat Community favor OCUL or ATAI? Ocular Therapeutix received 108 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 70.27% of users gave Ocular Therapeutix an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes44270.27% Underperform Votes18729.73% Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% SummaryOcular Therapeutix and Atai Life Sciences tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricAtai Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$275.65M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.726.7921.7117.82Price / Sales894.95225.97376.6894.61Price / CashN/A65.6738.1534.64Price / Book0.955.866.464.00Net Income-$40.22M$141.86M$3.20B$247.23M7 Day Performance6.92%4.38%2.76%1.44%1 Month Performance-6.08%-12.76%-8.61%-6.26%1 Year Performance-35.35%-11.13%10.39%0.59% Atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIAtai Life Sciences2.9246 of 5 stars$1.42+2.2%$10.50+639.4%-32.9%$281.60M$308,000.00-1.7580Positive NewsGap UpOCULOcular Therapeutix3.4345 of 5 stars$6.13-3.6%$16.38+167.1%-3.5%$978.78M$63.72M-4.66230Gap DownIOVAIovance Biotherapeutics4.2361 of 5 stars$2.96-1.5%$20.25+585.3%-72.8%$968.88M$164.07M-1.98500Analyst ForecastNews CoverageSNDXSyndax Pharmaceuticals3.3599 of 5 stars$10.84-3.6%$36.20+233.8%-47.6%$935.47M$23.68M-3.00110Gap DownCOLLCollegium Pharmaceutical4.167 of 5 stars$27.52-2.2%$43.60+58.4%-22.8%$887.49M$631.45M11.91210Positive NewsGap DownELVNEnliven Therapeutics2.5531 of 5 stars$17.90-4.2%$38.75+116.5%-14.5%$880.60MN/A-9.4650Gap UpWVEWave Life Sciences4.1623 of 5 stars$5.67-6.0%$22.60+298.9%+9.4%$874.87M$108.30M-5.14240Short Interest ↑Analyst RevisionGap DownDYNDyne Therapeutics3.5693 of 5 stars$7.36-11.1%$47.46+544.8%-69.1%$836.64MN/A-2.08100Positive NewsGap UpGPCRStructure Therapeutics2.5716 of 5 stars$14.28-5.6%$81.29+469.2%-49.8%$824.88MN/A-19.44136News CoverageCMRXChimerix2.7582 of 5 stars$8.53-0.1%$8.53+0.1%+834.8%$799.68M$212,000.00-9.0790Analyst ForecastCDMOAvid Bioservices0.7984 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies OCUL Competitors IOVA Competitors SNDX Competitors COLL Competitors ELVN Competitors WVE Competitors DYN Competitors GPCR Competitors CMRX Competitors CDMO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATAI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATAI Stock Free ATAI Stock Alerts